Role of dopamine in the recruitment of immune cells to the nigro-striatal dopaminergic structures

NeuroToxicology

Volumn 41, Issue , 2014, Pages 89-101

  Espinosa Oliva, Ana M ^a,b   de Pablos, Rocío M ^a,b   Sarmiento, Manuel ^a,b   Villarán, Ruth F ^a,b   Carrillo Jiménez, Alejandro ^a,b   Santiago, Marti ^a,b   Venero, José L ^a,b   Herrera, Antonio J ^a,b   Cano, Josefina ^a,b   Machado, Alberto ^a,b  

^a UNIVERSITY OF SEVILLE   (Spain)

^b Instituto de Biomedicina de Sevilla   (Spain)

Author keywords

Dopaminergic brain structures; Inflammation; Macrophages; Monocytes infiltration; Neurodegeneration

Indexed keywords

DOPAMINERGIC BRAIN STRUCTURES; INFLAMMATION; MACROPHAGES; MONOCYTES INFILTRATION; NEURODEGENERATION;

ALPHA-METHYLTYROSINE; ANIMALS; ASTROCYTES; CELL MOVEMENT; CORPUS STRIATUM; DOPAMINE; ENZYME INHIBITORS; INFLAMMATION; LYMPHOCYTES; MACROPHAGES; MALE; MOTOR ACTIVITY; NEURAL PATHWAYS; OSTEOPONTIN; OXIDOPAMINE; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; SYMPATHOLYTICS; TIME FACTORS;

EID: 84893911408     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2014.01.006     Document Type: Article

References (57)

1. Abram C.L., Lowell C.A. The ins and outs of leukocyte integrin signaling. Annu Rev Immunol 2009, 7:339-362.
2. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973, 20:415-455.
3. Brochard V., Combadiere B., Prigent A., Laouar Y., Perrin A., Beray-Berthat V., et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009, 119:182-192.
4. Carlson S.L., Fox S., Abell K.M. Catecholamine modulation of lymphocyte homing to lymphoid tissues. BMC Immunol 2009, 10:62.
5. Carstam R., Brinck C., Hindemith-Augustsson A., Rorsman H., Rosengren E. The neuromelanin of the human substantia nigra. Biochim Biophys Acta 1991, 1097(September (2)):152-160.
6. Castaño A., Herrera A.J., Cano J., Machado A. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem 1998, 70:1584-1592.
7. Castaño A., Herrera A.J., Cano J., Machado A. The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma. J Neurochem 2002, 81:150-157.
8. Chen X., Lan X., Roche I., Liu R., Geiger J.D. Caffeine protects against MPTP-induced blood-brain barrier dysfunction in mouse striatum. J Neurochem 2008, 107:1147-1157.
9. Chesselet M.F. Dopamine and Parkinson's disease: is the killer in the house?. Mol Psychiatry 2003, 8:369-370.
10. Cho B.P., Song D.Y., Sugama S., Shin D.H., Shimizu Y., Kim S.S., et al. Pathological dynamics of activated microglia following medial forebrain bundle transection. Glia 2006, 53:92-102.
11. Cho B.P., Sugama S., Shin D.H., DeGiorgio L.A., Kim S.S., Kim Y.S., et al. Microglial phagocytosis of dopamine neurons at early phases of apoptosis. Cell Mol Neurobiol 2003, 23:551-560.
12. Choi H.J., Kim S.W., Lee S.Y., Hwang O. Dopamine-dependent cytotoxicity of tetrahydrobiopterine: a possible mechanism for selective neurodegeneration in Parkinson's disease. J Neurochem 2003, 86:143-152.
13. De Pablos R.M., Herrera A.J., Villarán R.F., Cano J., Machado A. Dopamine-dependent neurotoxicity of lipopolysaccharide in substantia nigra. FASEB J 2005, 19:407-409.
14. Dong Z., Ferger B., Paterna J.C., Vogel D., Furler S., Osinde M., et al. Dopamine-dependent neurodegeneration in rats induced by viral vector-mediated overexpression of the parkin target protein, CDCrel-1. Proc Natl Acad Sci USA 2003, 100:12438-12443.
15. Faucheux B.A., Bonnet A.M., Agid Y., Hirsch E.C. Blood vessels change in the mesencephalon of patients with Parkinson's disease. Lancet 1999, 353:981-982.
16. Faull R.L., Laverty R. Changes in dopamine levels in the corpus striatum following lesions in the substantia nigra. Exp Neurol 1969, 23:332-340.
17. Gao H.M., Jiang J., Wilson B., Zhang W., Hong J.S., Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem 2002, 81:1285-1297.
18. German D.C., Nelson E.L., Liang C.L., Speciale S.G., Sinton C.M., Sonsalla P.K. The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. Neurodegeneration 1996, 5:299-312.
19. Gundersen H.J., Bagger P., Bendtsen T.F., Evans S.M., Korbo L., Marcussen N., et al. The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS 1988, 96:857-881.
20. Hasbani D.M., Perez F.A., Palmiter R.D., O'Malley K.L. Dopamine depletion does not protect against acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in vivo. J Neurosci 2005, 25:9428-9433.
21. Herrera A.J., Castaño A., Venero J.L., Cano J., Machado A. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol Dis 2000, 7:429-447.
22. Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol 2009, 8:382-397.
23. Jeon B.S., Jackson-Lewis V., Burke R.E. 6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death. Neurodegeneration 1995, 4:131-137.
24. Kim W.G., Mohney R.P., Wilson B., Jeohn G.H., Liu B., Hong J.S. Regional difference in susceptibility to lipopolysaccharideinduced neurotoxicity in the rat brain: role of microglia. J Neurosci 2000, 20:6309-6316.
25. Kortekaas R., Leenders K.L., van Oostrom J.C., Vaalburg W., Bart J., Willemsen A.T., et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 2005, 57:176-179.
26. Kostrzewa R.M., Jacobowitz D.M. Pharmacological actions of 6-hydroxydopamine. Pharmacol Rev 1974, 26:199-288.
27. Kurkowska-Jastrzebska I., Wronska A., Kohutnicka M., Czlonkowski A., Czlonkowska A. MHC class II positive microglia and lymphocytic infiltration are present in the substantia nigra and striatum in mouse model of Parkinson's disease. Acta Neurobiol Exp (Wars) 1999, 59:1-8.
28. Langston J.W., Forno L.S., Tetrud J., Reeves A.G., Kaplan J.A., Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999, 46:598-605.
29. Man S., Ubogu E.E., Ransohoff R.M. Inflammatory cell migration into the central nervous system: a few new twists on an old tale. Brain Pathol 2007, 17:243-250.
30. Manzanero S. Generation of mouse bone marrow-derived macrophages. Methods Mol Biol 2012, 844:177-181.
31. Marinova-Mutafchieva L., Sadeghian M., Broom L., Davis J.B., Medhurst A.D., Dexter D.T. Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease. J Neurochem 2009, 110:966-975.
32. McGeer P.L., Itagaki S., Akiyama H., McGeer E.G. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 1988, 24:574-576.
33. McGeer P.L., Itagaki S., Akiyama H., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
34. McGeer P.L., Itagaki S., McGeer E.G. Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol (Berl) 1988, 76:550-557.
35. Miklossy J., Doudet D.D., Schwab C., Yu S., McGeer E.G., McGeer P.L. Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Exp Neurol 2006, 197:275-283.
36. Na S.J., DiLella A.G., Lis E.V., Jones K., Levine D.M., Stone D.J., et al. Molecular profiling of a 6-hydrodopamine model of Parkinson's disease. Neurochem Res 2010, 35:761-772.
37. Nguyen A., Gille G., Moldzio R., Hung S.T., Rausch W.D. Synthetic neuromelanin is toxic to dopaminergic cell cultures. J Neural Transm 2002, 109(May (5-6)):651-661.
38. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1986, Academic Press, San Diego. 2nd ed.
39. Rite I., Machado A., Cano J., Venero J.L. Blood-brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons. J Neurochem 2007, 101:1567-1582.
40. Rodriguez M., Alvarez-Erviti L., Blesa F.J., Rodríguez-Oroz M.C., Arina A., Melero I., et al. Bone-marrow-derived cell differentiation into microglia: a study in a progressive mouse model of Parkinson's disease. Neurobiol Dis 2007, 28:316-325.
41. Sakka N., Sawada H., Izumi Y., Katsuki H., Kaneko S., Shimohama S., et al. Dopamine is involved is selectivity of dopaminergic neuronal death by rotenone. Neuroreport 2003, 14:2425-2428.
42. Santiago M., Matarredona E.R., Granero L., Cano J., Machado A. Neurotoxic relationship between dopamine and iron in the striatal dopaminergic nerve terminals. Brain Res 2000, 858:26-32.
43. Schmidt C.J., Ritter J.K., Sonsalla P.K., Hanson G.R., Gibb J.W. Role of dopamine in the neurotoxic effects of methamphetamine. J Pharmacol Exp Ther 1985, 233:539-544.
44. Shima T., Sarna T., Swartz H.M., Stroppolo A., Gerbasi R., Zecca L. Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study. Free Radic Biol Med 1997, 23:110-119.
45. Strell C., Sievers A., Bastian P., Lang K., Niggemann B., Zänker K.S., et al. Divergent effects of norepinephrine, dopamine and substance P on the activation, differentiation and effector functions of human cytotoxic T lymphocytes. BMC Immunol 2009, 10:62.
46. Sugama S., Yang L., Cho B.P., DeGiorgio L.A., Lorenzl S., Albers D.S., et al. Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res 2003, 964:288-294.
47. Thomas D.M., Francescutti-Verbeem D.M., Kuhn D.M. The newly synthesized pool of dopamine determines the severity of methamphetamine-induced neurotoxicity. J Neurochem 2008, 105:605-616.
48. Tomás-Camardiel M., Rite I., Herrera A.J., de Pablos R.M., Cano J., Machado A., et al. Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system. Neurobiol Dis 2004, 16:190-201.
49. Van Rooijen N., Sanders A., van den Berg T.K. Apoptosis of macrophages induced by liposome-mediated intracellular delivery of clodronate and propamidine. J Immunol Methods 1996, 193:93-99.
50. Venero J.L., Santiago M., Machado A., Cano J. Determination of monoamines and both forms of monoamine oxidase in the rat' substantia nigra during postnatal development. Life Sci 1989, 45:1277-1283.
51. Villarán R.F., Espinosa-Oliva A.M., Sarmiento M., de Pablos R.M., Argüelles S., Delgado-Cortés M.J., et al. Ulcerative colitis exacerbates LPS-induced damage to the nigral dopaminergic system: potential risk factor in Parkinson's disease. J Neurochem 2010, 114:1687-1700.
52. Wagner G.C., Lucot J.B., Schuster C.R., Seiden L.S. Alpha-methyltyrosine attenuates and reserpine increases methamphetamine-induced neuronal changes. Brain Res 1983, 270:285-288.
53. Watanabe Y., Nakayama T., Nagakubo D., Hieshima K., Jin Z., Katou F., et al. Dopamine selectively induces migration and homing of naive CD8+ T cells via dopamine receptor D3. J Immunol 2006, 176:848-856.
54. Xu G., Gonzales V., Borchelt D.R. Rapid detection of protein aggregates in the brains of Alzheimer patients and transgenic mouse models of amyloidosis. Alzheimer Dis Assoc Disord 2002, 16:191-195.
55. Yan E., Castillo-Melendez M., Nicholls T., Hirst J., Walker D. Cerebrovascular responses in the fetal sheep brain to low-dose endotoxin. Pediatric Res 2004, 55:855-863.
56. Yasuda T., Fukuda-Tani M., Nihira T., Wada K., Hattori N., Mizuno Y., et al. Correlation between levels of pigment epithelium-derived factor and vascular endothelial growth factor in the striatum of patients with Parkinson's disease. Exp Neurol 2007, 206:308-317.
57. Zucca F.A., Basso E., Cupaioli F.A., Ferrari E., Sulzer D., Casella L., et al. Neuromelanin of the human substantia nigra: an update. Neurotox Res 2013, (October). [Epub ahead of print].